1. Hu, J., X.F. Cai, and G. Yan, Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1/CIP1 protein. Cell Cycle, 2009. 8(20): p. 3328-39.DOI:10.4161/cc.8.20.9832

2. Lin, Y., e t al., Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci U S A, 2014. 111(42): p. E4504-12.DOI:10.1073/pnas.1408759111

3. Li, K., et al., A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1. Oncotarget, 2016. 7(30): p. 48443-48455.DOI:10.18632/oncotarget.10305

4. Li, K., et al., Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. Mol Ther, 2016. 24(1): p. 156-65.DOI:10.1038/mt.2015.172

5. Zhang, H., et al., Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. Hum Gene Ther, 2016. 27(9): p. 700-11.DOI:10.1089/hum.2016.038

6. Cai, J., et al., Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A, 2017. 114(26): p. 6812-6817

7. Tan, Y., et al., Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial Apoptosis. Hum Gene Ther, 2017.DOI:10.1089/hum.2017.055

8. Ying, L., et al., Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. Oncotarget, 2017. 8(15): p. 24694-24705.DOI:10.18632/oncotarget.15788

9. Zhang, H., et al., Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med, 2017. 9(404): p. eaam7996.DOI:10.1126/scitranslmed.aam7996

10. Hu, C., et al., Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. Cell Death Dis, 2018. 9(3): p. 274.DOI:10.1038/s41419-018-0325-3

11. Li, K., et al., Deficiency of the IRE1alpha-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1. J Virol, 2018. 92(6).DOI:10.1128/JVI.01331-17

12. Liang, J., et al., Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus. Nat Commun, 2018. 9(1): p. 1524.DOI:10.1038/s41467-018-03913-6

13. Xiao, X., et al., DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat Commun, 2018. 9(1): p. 4342.DOI:10.1038/s41467-018-06771-4

14. Wang, Y., et al., Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo. Mol Pharm, 2019. 16(2): p. 779-785.DOI:10.1021/acs.molpharmaceut.8b01046

15. Cai, J. and J. Liang, Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity. Cancer cell international, 2020

16. Cai, J., et al., Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol Oncol, 2020.DOI:10.1002/1878-0261.12820

17. Cai, J., et al., Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene, 2020. 39(37): p. 5995-6008.DOI:10.1038/s41388-020-01416-7

18. Cai, J., et al., Systematic Characterization of the Biodistribution of the Oncolytic Virus M1. Hum Gene Ther, 2020.DOI:10.1089/hum.2020.114

19. Qin, Z., et al., Establishment and evaluation of a TaqMan RT-qPCR method for tissue quantification of oncolytic virus M1 in vivo. Chinese Journal of Pathophysiology, 2020. 36(5): p. 950-960